// App-Quantinova.ai

: Baseline Characteristics of All Patients Randomized in a Phase IIb Trial of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension

Researchers

Presenter

  • J. Behr

Principal Investigators

  • S. D. Nathan

  • S. Harari

  • W. Wuyts

  • N. Mogulkoc Bishop

  • D. E. Bouros

  • K. Antoniou

  • J. Guiot

  • M. Kramer

  • K. Kirchgaessler

  • M. Bengus

  • F. Gilberg

  • A. U. Wells

Medical Centers

  • Internal Medicine V, University of Munich, Comprehensive Pneumology Ctr., Munchen, Germany,

  • Inova Fairfax Hospital, Falls Church, Virginia, United States

  • U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria, Servizio di Fisiopatologia Respiratoriea, Ospedale San Giuseppe, MultiMedica IRCCS, Milan, Italy,

  • Department of Pulmonary Medicine, Unit for Interstitial Lung Diseases, University of Leuven, Leuven, Belgium,

  • Department of Pulmonary Medicine, Unit for Interstitial Lung Diseases, Ege University Hospital, Izmir, Turkey,

  • National and Kapodistrian University of Athens, Athens, Greece

  • Department of Thoracic Medicine, University of Crete, Heraklion, Crete, Greece,

  • Respiratory Department and GIGA-13 Research Unit, CHU Liège, Liege, Belgium,

  • Pulmonary Institute, Rabin Medical Center, Petach-Tikva, Israel

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

  • Pulmonary arterial hypertension

  • Pulmonary fibrosis

  • Hypertension

Biomarkers

  • N/A

Drug/Treatment

  • Pirfenidone

  • Sildenafil citrate

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved